You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine) injection
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How are patients transitioned from insulin degludec to Basaglar® (insulin glargine)?
Basaglar has not been studied in patients previously on insulin degludec. Therefore, if transitioning from insulin degludec to Basaglar, a different dose of Basaglar and concomitant antihyperglycemic therapies may be needed.
This content was last updated on September 30, 2025. Literature published after this date may not be reflected in the content. Please refer to the [link to USPI], Medical.lilly.com and PubMed for additional information on this topic.
Transitioning From Insulin Degludec to Basaglar
Basaglar® (insulin glargine) 100 units/mL has not been studied in patients previously on insulin degludec.
Dose Comparison Between Insulin Glargine and Insulin Degludec
Based on patient-level meta-analyses that were performed on 7 phase 3a trials that compared insulin degludec with insulin glargine (Daily Mean Dose of Insulin Glargine and Insulin Degludec at End of Trial), a transition from insulin degludec to Basaglar may be made on a unit-to-unit basis. The dose of Basaglar may require up titration for
- basal-bolus-treated patients with type 1 diabetes, and
- insulin-naive patients with type 2 diabetes.1
Category |
Insulin Glargine |
Insulin Degludec |
Dose Difference |
P Value |
T1DB/B |
0.77 units/kg |
0.68 units/kg |
12% |
<.0001 |
T2Dinsulin-naive |
0.43 units/kg |
0.39 units/kg |
10% |
.0004 |
T2DB/B |
1.18 units/kg |
1.22 units/kg |
0% |
NS |
Abbreviations: NS = not significant; T1DB/B = basal-bolus-treated patients with type 1 diabetes; T2DB/B = basal-bolus-treated patients with type 2 diabetes; T2Dinsulin-naïve = insulin-naive patients with type 2 diabetes.
General Dosing Guidelines When Transitioning to Basaglar
If transitioning from a treatment regimen with an intermediate- or long-acting insulin to a regimen with Basaglar, a change in the dose of the basal insulin may be required.2
Patients may be predisposed to hypoglycemia or hyperglycemia by changes in insulin
- strength
- manufacturer
- type
- injection site, or
- method of administration.2
Insulin treatment changes should be made
- under close medical supervision, and
- with increased frequency of blood glucose monitoring.2
In patients with type 2 diabetes, dosage adjustments of concomitant antihyperglycemic medications may be needed.2
Enclosed Prescribing Information
References
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435-446. http://dx.doi.org/10.1007/s13300-014-0076-9
2Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: September 30, 2025